^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

ATA3219

i
Other names: ATA3219
Company:
Atara
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
2ms
Enrollment change • CAR T-Cell Therapy
|
ATA3219
6ms
New P1 trial • CAR T-Cell Therapy
|
ATA3219
9ms
New P1 trial
|
BCL2 (B-cell CLL/lymphoma 2)
|
ATA3219
almost2years
Optimization and Characterization of ATA3219: A Novel and Potent Allogeneic CD19-CAR T Therapy without Gene-Editing (TCT-ASTCT-CIBMTR 2023)
This updated preclinical dataset for ATA3219 demonstrates the flexibility of our EBV T-cell manufacturing process through improvements in the polyfunctional phenotype, potent expansion and targeting against B cell tumors with low alloreactivity. These findings support advancing ATA3219 to clinical evaluation.
IO biomarker
|
CD19 (CD19 Molecule)
|
ATA3219
almost4years
[VIRTUAL] ATA3219: A Potent Next-Generation Allogeneic Off-the-Shelf CD19 CAR-T Therapy without the Need for Gene Editing (TCT-ASTCT-CIBMTR 2021)
Conclusions This preclinical dataset for CD19-1XX CAR+ EBV T cells demonstrates persistence, polyfunctional phenotype and efficient targeting of CD19-expressing tumor cells in vitro and in vivo, with limited allocytoxicity against antigen-negative, HLA-mismatched targets. These findings support advancing ATA3219 to clinical evaluation.
IO biomarker
|
CD19 (CD19 Molecule)
|
CD19 expression
|
ATA3219
almost4years
[VIRTUAL] ATA3219: A Potent Next-Generation Allogeneic Off-the-Shelf CD19 CAR-T Therapy without the Need for Gene Editing (TCT-ASTCT-CIBMTR 2021)
Conclusions This preclinical dataset for CD19-1XX CAR+ EBV T cells demonstrates persistence, polyfunctional phenotype and efficient targeting of CD19-expressing tumor cells in vitro and in vivo, with limited allocytoxicity against antigen-negative, HLA-mismatched targets. These findings support advancing ATA3219 to clinical evaluation.
IO biomarker
|
CD19 (CD19 Molecule)
|
CD19 expression
|
ATA3219
almost4years
[VIRTUAL] ATA3219: A Potent Next-Generation Allogeneic Off-the-Shelf CD19 CAR-T Therapy without the Need for Gene Editing (TCT-ASTCT-CIBMTR 2021)
Conclusions This preclinical dataset for CD19-1XX CAR+ EBV T cells demonstrates persistence, polyfunctional phenotype and efficient targeting of CD19-expressing tumor cells in vitro and in vivo, with limited allocytoxicity against antigen-negative, HLA-mismatched targets. These findings support advancing ATA3219 to clinical evaluation.
IO biomarker
|
CD19 (CD19 Molecule)
|
CD19 expression
|
ATA3219
almost4years
[VIRTUAL] ATA3219: A Potent Next-Generation Allogeneic Off-the-Shelf CD19 CAR-T Therapy without the Need for Gene Editing (TCT-ASTCT-CIBMTR 2021)
Conclusions This preclinical dataset for CD19-1XX CAR+ EBV T cells demonstrates persistence, polyfunctional phenotype and efficient targeting of CD19-expressing tumor cells in vitro and in vivo, with limited allocytoxicity against antigen-negative, HLA-mismatched targets. These findings support advancing ATA3219 to clinical evaluation.
IO biomarker
|
CD19 (CD19 Molecule)
|
CD19 expression
|
ATA3219
almost4years
[VIRTUAL] ATA3219: A Potent Next-Generation Allogeneic Off-the-Shelf CD19 CAR-T Therapy without the Need for Gene Editing (TCT-ASTCT-CIBMTR 2021)
Conclusions This preclinical dataset for CD19-1XX CAR+ EBV T cells demonstrates persistence, polyfunctional phenotype and efficient targeting of CD19-expressing tumor cells in vitro and in vivo, with limited allocytoxicity against antigen-negative, HLA-mismatched targets. These findings support advancing ATA3219 to clinical evaluation.
IO biomarker
|
CD19 (CD19 Molecule)
|
CD19 expression
|
ATA3219
4years
[VIRTUAL] ATA3219: A Potent Next-Generation Allogeneic Off-the-Shelf CD19-CAR T Therapy without the Need for Gene-Editing (ASH 2020)
CONCLUSIONS This preclinical dataset for CD19-1XX CAR+ EBV T cells demonstrate, persistence, polyfunctional phenotype and efficient targeting of CD19-expressing tumor cells, both in vitro and in vivo, with limited allocytoxicity against antigen-negative, HLA-mismatched targets. These findings support advancing ATA3219 to clinical evaluation.
IO biomarker
|
CD19 (CD19 Molecule)
|
CD19 expression
|
ATA3219